Abstract
More than 50 % of the marine cyanobacteria are potentially exploitable for extracting bioactive substances, which are effective in killing the cancer cells. Cyanobacterial metabolites exhibit a wide range of biological effects and some of these metabolites possess potential cytotoxic activities to different mammalian cell lines. The various cyanobacterial compounds with potential anticancer properties and their cytotoxicity are discussed in this chapter. Cyanobacteria also produce a wide range of compounds that revealed apoptotic properties. Potential cyanobacterial compounds with apoptotic properties and their use as drug delivery system with cellular targets are also discussed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Andrianasolo EH, Gross H, Goeger D, Musafija-Girt M, McPhail K, Leal RM, Mooberry SL, Gerwick WH (2005) Isolation of swinholide A and related glycosylated derivatives from two field collections of marine cyanobacteria. Org Lett 7:1375–1378
Barchi JJ, Bortin TR, Furusawa E, Patterson GLM, Moore RE (1983) Identification of a cytotoxin from Tolypothrix byssoidea as tubericin. Phytochemistry 22:2851–2852
Bernardo PH, Chai CL, Le Guen M, Smith GD, Waring P (2007) Structure-activity delineation of quinones related to the biologically active calothrixin B. Bioorg Med Chem Lett 17:82–85
Berry JP, Gantar M, Gawley RE, Wang M, Rein KS (2004) Pharmacology and toxicology of pahayokolide A, a bioactive metabolite from a freshwater species of Lyngbya isolated from the Florida Everglades. Comp Biochem Physiol C 139:231–238
Biondi N, Piccardi R, Margheri MC, Rodolfi L, Smith GD, Tredici MR (2004) Evaluation of Nostoc strain ATCC 53789 as a potential source of natural pesticides. Appl Environ Microbiol 70:3313–3320
Chang TT, More SV, Lu IH, Hsu JC, Chen TJ, Jen YC, Lu CK, Li WS (2011) Isomalyngamide A, A–1 and their analogs suppress cancer cell migration in vitro. Eur J Med Chem 46:3810–3819
Chen X, Smith GD, Waring P (2003) Human cancer cell (Jurkat) killing by the cyanobacterial metabolite calothrixin A. J Appl Phycol 15:269–277
Cole KE, Dowling DP, Boone MA, Phillips AJ, Christianson DW (2011) Structural basis of the antiproliferative activity of largazole, a depsipeptide inhibitor of the histone deacetylases. J Am Chem Soc 133:12474–12477
Cruz RD, Tricot G, Zangari M, Zhan F (2011) Progress in myeloma stem cells. Am J Blood Res 1:135–45
Davis ME, Chen Z, Shin DM (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7:771–782
Earnshaw WC, Martins LM, Kaufmann SH (1999) Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 68:383–424
Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35:495–516
Feng SS, Chien S (2003) Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem Eng Sci 58:4087–4114
Fischer U, Schulze-Osthoff K (2005) Apoptosis-based therapies and drug targets. Cell Death Differ 12:942–961
Fischer WJ, Hitzfeld BC, Tencalla F, Eriksson JE, Mikhailov A, Dietrich DR (2000) Microcystin-LR toxicodynamics, induced pathology, and immunohistochemical localization in livers of blue-green algae exposed rainbow trout (Oncorhynchus mykiss). Toxicol Sci 54:365–373
Fladmark KE, Brustugun OT, Hovland R, Boe R, Gjertsen BT, Zhivotovsky B, Doskeland SO (1999) Ultrarapid caspase-3 dependent apoptosis induction by serine/threonine phosphatase inhibitors. Cell Death Differ 6:1099–1108
Galluzzi L, Kepp O, Trojel-Hansen C, Kroemer G (2012) Mitochondrial control of cellular life, stress, and death. Circ Res 111:1198–1207
Garattini S, La Vecchia C (2001) Perspectives in cancer chemotherapy. Eur J Cancer 37:128–47
Geiger M, Li RH, Friess W (2003). Collagen sponges for bone regeneration with rhBMP-2. Adv Drug Deliv Rev 55:1613–1629
Gunasekera SP, Owle CS, Montaser R, Luesch H, Paul VJ (2011) Malyngamide 3 and cocosamides A and B from the marine cyanobacterium Lyngbya majuscula from Cocos Lagoon, Guam. J Nat Prod 74:871–6
Gupta N, Pant SC, Vijayaraghavan R, Rao PV (2003) Comparative toxicity evaluation of cyanobacterial cyclic peptide toxin microcystin variants (LR, RR, YR) in mice. Toxicology 188: 285–296
Gupta, S, Kass GE, Szegezdi E, Joseph B (2009) The mitochondrial death pathway: a promising therapeutic target in diseases. J Cell Mol Med 13:1004–1033
Hambley TW, Hait WN (2009) Is anticancer drug development heading in the right direction? Cancer Res 69:1259–1262
Han B, Goeger D, Maier CS, Gerwick WH (2005) The wewakpeptins, cyclic depsipeptides from a Papua New Guinea collection of the marine cyanobacterium Lyngbya semiplena. J Org Chem 70:3133–3139
Hooser SB (2000) Fulminant hepatocyte apoptosis in vivo following microcystin-LR administration to rats. Toxicol Pathol 28:726–733
Humpage AR, Fontaine F, Froscio S, Burcham P, Falconer IR (2005) Cylindrospermopsin genotoxicity and cytotoxicity: role of cytochrome P-450 and oxidative stress. J Toxicol Env Heal A 68:739–753
Itoh T, Tsuzuki R, Tanaka T, Ninomiya M, Yamaguchi Y, Takenaka H, Ando M, Tsukamasa Y, Koketsu M (2013) Reduced scytonemin isolated from Nostoc commune induces autophagic cell death in human T-lymphoid cell line Jurkat cells. Food Chem Toxicol 60:76–82
Jones AC, Monroe EA, Eisman EB, Gerwick L, Sherman DH, Gerwick WH (2010) The unique mechanistic transformations involved in the biosynthesis of modular natural products from marine cyanobacteria. Nat Prod Rep 27:1048–1065
Kalemkerian GP, Ou XL, Adil MR, Rosati R, Khoulani MM, Madan SK, Pettit GR (1999) Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification. Cancer Chemother Pharmacol 43:507–515
Kroemer G (2003) Mitochondrial control of apoptosis: an introduction. Biochem Biophys Res Commun 304:433–435
Kwan JC, Rocca JR, Abboud KA, Paul VJ, Luesch H (2008) Total structure determination of grassypeptolide: a new marine cyanobacterial cytotoxin. Org Lett 10:789–92
Lamelin JP, Vassalli P (1978) Heterogeneity of the B cell subpopulation operationally defined by (a) differentiation antigen(s) common to MOPC 104E and mature IgM plasma cells. Immunology 35:885–888
Lee HU, Park SY, Park ES, Son B, Lee SC, Lee JW, Lee YC, Kang KS, Kim MI, Park HG, Choi S, Huh YS, Lee SY, Lee KB, Oh YK, Lee J (2014) Photoluminescent carbon nanotags from harmful cyanobacteria for drug delivery and imaging in cancer cells. Sci Rep 4:4665
LePage KT, Goeger D, Yokokawa F, Asano T, Shioiri T, Gerwick WH, Murray TF (2005) The neurotoxic lipopeptide kalkitoxin interacts with voltage-sensitive sodium channels in cerebellar granule neurons. Toxicol Lett 158:133–139
Liu L, Herfindal L, Jokela J, Shishido TK, Wahlsten M, Døskeland SO, Sivonen K (2014) Cyanobacteria from terrestrial and marine sources contain apoptogens able to overcome chemoresistance in acute myeloid leukemia cells. Mar Drugs 12:2036–2053
Lu W, Yu P, Li J (2011) Induction of apoptosis in human colon carcinoma COLO 205 cells by the recombinant alpha subunit of C-phycocyanin. Biotechnol Lett 33:637–644
Luesch H, Yoshida WY, Moore RE, Paul VJ, Mooberry SL (2000) Isolation, structure determination, and biological activity of lyngbyabellin A from the marine cyanobacterium Lyngbya majuscula. J Nat Prod 63:611–615
Luesch H, Moore RE, Paul VJ, Mooberry SL, Corbett TH (2001a) Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1. J Nat Prod 64:907–910
Luesch H, Yoshida WY, Moore RE, Paul VJ, Corbett TH (2001b) Total structure determination of apratoxin A, a potent novel cytotoxin from the marine cyanobacterium Lyngbya majuscula. J Am Chem Soc 123:5418–5423
Lytvyn DI, Yemets AI, Blume YB (2010) UV-B overexposure induces programmed cell death in a BY-2 tobacco cell line. Environ Exp Bot 68:51–57
MacKintosch C, Beattie KA, Klumpp S, Cohen P, Codd GA (1990) Cyanobacterial microcystin-LR is a potent and specific inhibitor of protein phosphatases 1 and 2A from both mammals and higher plants. FEBS Lett. 264:187–192
MacKintosh RW, Dalby KN, Campbell DG, Cohen PT, Cohen P, MacKintosh C (1995) The cyanobacterial toxin microcystin binds covalently to cysteine-273 on protein phosphatase 1. FEBS Lett 371:236–240
Malloy KL, Choi H, Fiorilla C, Valeriote FA, Matainaho T, Gerwick WH (2012) Hoiamide D, a marine cyanobacteria-derived inhibitor of p53/MDM2 interaction. Bioorg Med Chem Lett 22:683–688
Mao YB, Song G, Cai QF, Liu M, Luo HH, Shi MX, Ouyang G, Bao SD (2006) Hydrogen peroxide-induced apoptosis in human gastric carcinoma MGC803 cells. Cell Biol Int 30:332–337
Marquez BL, Watts KS, Yokochi A, Roberts MA, Verdier-Pinard P, Jimenez JI, Hamel E, Scheuer PJ, Gerwick WH (2002) Structure and absolute stereochemistry of hectochlorin, a potent stimulator of actin assembly. J Nat Prod 65:866–871
Martins RF, Ramos MF, Herfindal L, Sousa JA, Skaerven K, Vasconcelos VM (2008) Antimicrobial and cytotoxic assessment of marine cyanobacteria—Synechocystis and Synechococcus. Mar Drugs 6:1–11
McCarty MF (2007) Clinical potential of Spirulina as a source of phycocyanobilin. J Med Food 10:566–570
Medina RA, Goeger DE, Hills P, Mooberry SL, Huang N, Romero LI, Ortega-Barria E, Gerwick WH, McPhail KL (2008) Coibamide A, a potent antiproliferative cyclic depsipeptide from the Panamanian marine cyanobacterium Leptolyngbya sp. J Am Chem Soc 130:6324–6325
Meickle T, Matthew S, Ross C, Luesch H, Paul V (2009) Bioassay-guided isolation and identification of desacetyl-microcolin B from Lyngbya cf. polychroa. Planta Med 75:1427–30
Metcalf JS, Lindsay J, Beattie KA, Birmingham S, Saker ML, Törökné AK, Codd GA (2002) Toxicity of cylindrospermopsin to the brine shrimp Artemia salina comparisons with protein synthesis inhibitors and microcystins. Toxicon 40:1115–1120
Mevers E, Liu W, Engene N, Mohimani H, Byrum T, Pevzner PA, Dorrestein PC, Spadafora C, Gerwick WH (2011) Cytotoxic veraguamides, alkynyl bromide-containing cyclic depsipeptides from the marine cyanobacterium cf. Oscillatoria margaritifera. J Nat Prod 74:928–936
Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6:583–592
Morlière P, Mazière JC, Santus R, Smith CD, Prinsep MR, Stobbe CC, Fenning MC, Golberg JL, Chapman JD (1998) Tolyporphin: a natural product from cyanobacteria with potent photosensitizing activity against tumor cells in vitro and in vivo. Cancer Res 58:3571–3578
Murakami M, Sun Q, Ishida K, Matsuda H, Okino T, Yamuguchi K (1997) Microviridins, elastase inhibitors from the cyanobacterium Nostoc minutum (NIES-26). Phytochemistry 45:1997–1202
Muta T, Miyamoto T, Fujisaki T, Ohno Y, Kamimura T, Henzan T, Kato K, Takenaka K, Iwasaki H, Eto T, Takamatsu Y, Teshima T, Akashi K (2013) Effect of bortezomib-based induction therapy on the peripheral blood stem cell harvest in multiple myeloma. Rinsho Ketsueki 54:109–16
Nagarajan M, Maruthanayagam V, Sundararaman M (2012) A review of pharmacological and toxicological potentials of marine cyanobacterial metabolites. J Appl Toxicol 32:153–185
Nair S, Bhimba BV (2013) Bioactive potency of cyanobacteria Oscillatoria spp. Int J Pharm Pharm Sci 5:611–612
Nogle LM, Gerwick WH (2002) Somocystinamide A, a novel cytotoxic disulfide dimer from a Fijian marine cyanobacterial mixed assemblage. Org Lett 4:1095–1098
Nogle LM, Okino T, Gerwick WH (2001) Antillatoxin B, a neurotoxic lipopeptide from the marine cyanobacterium Lyngbya majuscula. J Nat Prod 64:983–985
Nunnery JK, Mevers E, Gerwick WH (2010) Biologically active secondary metabolites from marine cyanobacteria. Curr Opin Biotechnol 21:787–793
Oftedal L, Selheim F, Wahlsten M, Sivonen K, Doskeland SO, Herfindal L (2010) Marine benthic cyanobacteria contain apoptosis-inducing activity synergizing with daunorubicin to kill leukemia cells, but not cardiomyocytes. Mar Drugs 8:2659–2672
Oftedal L, Skjaerven KH, Coyne RT, Edvardsen B, Rohrlack T, Skulberg OM, Døskeland SO, Herfindal L (2011) The apoptosis-inducing activity towards leukemia and lymphoma cells in a cyanobacterial culture collection is not associated with mouse bioassay toxicity. J Ind Microbiol Biotechnol 38:489–501
Ou Y, Xu S, Zhu D, Yang X (2014) Molecular mechanisms of exopolysaccharide from Aphanothece halaphytica (EPSAH) induced apoptosis in HeLa cells. PloS ONE 9:e87223
Ozoren N, El-Deiry WS (2003) Cell surface death receptor signaling in normal and cancer cells. Semin Cancer Biol 13:135–147
Patterson GM, Carmeli S (1992) Biological effects of tolytoxin (6-hydroxy-7-O-methyl-scytophycin b) a potent bioactive metabolite from cyanobacteria. Ach Microbiol 157:406–410
Patterson GML, Smith CD, Kimura LH, Britton BA, Carmeli S (1993) Action of tolytoxin on cell morphology, cytoskeletal organization, and actin polymerization. Cell Motil Cytoskeleton 24:39–48
Prinsep MR, Caplan FR, Moore RE, Patterson GM, Smith CD (1992) Tolyporphin, a novel multidrug resistance-reversing agent from the blue-green alga Tolypothrix nodosa. J Am Chem Soc 114:385–387
Proteau PJ, Gerwick WH, Garcia-Pichel F, Castenholz R (1993) The structure of scytonemin, an ultraviolet sunscreen pigment from the sheaths of cyanobacteria. Experientia 49:825–9
Rodney WR, Rothschild JM, Willis AC, Chazal NM, Kirk J, Saliba KJ, Smith GD (1999) Calothrixin A and B, novel pentacyclic metabolites from Calothrix cyanobacteria with potent activity against malaria parasites and human cancer cells. Tetrahedron 55:13513–13520
Rubio BK, Parrish SM, Yoshida W, Schupp PJ, Schils T, Williams PG (2010) Depsipeptides from a Guamanian marine cyanobacterium, Lyngbya bouillonii, with selective inhibition of serine proteases. Tetrahedron Lett 51:6718–6721
Sainis I, Fokas D, Vareli K, Tzakos AG, Kounnis V, Briasoulis E (2010) Cyanobacterial cyclopeptides as lead compounds to novel targeted cancer drugs. Mar Drugs 8:629–657
Salvador LA, Paul VJ, Luesch H, Caylobolide B (2010) a macrolactone from symplostatin1-producing marine cyanobacteria Phormidium spp. from Florida. J Nat Prod 73:1606–1609
Schirmer T, Huber R, Schneider M, Bode W, Miller M, Hackert ML (1986) Crystal structure analysis and refinement at 2.5 Å of hexameric C-phycocyanin from the cyanobacterium Agmenellum quadruplicatum: the molecular model and its implications for light-harvesting. J Mol Biol 188:651–676
Senthilkumar CS, Ganesh N (2012) Lenalidomide-based combined therapy induced alterations in serum proteins of multiple myeloma patient: a follow-up case report and overview of the literature. Exp Oncol 34:373–376
Shi J, Votruba AR, Farokhzad OC, Langer R (2010) Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Letters 10:3223–3230
Shih C, Teicher BA (2001) Cryptophycins: a novel class of potent antimitotic antitumor depsipeptides. Curr Pharm Des 7:1259–1276
Simmons TL, McPhail KL, Ortega-Barrı´a E, Mooberry SL, Gerwick WH (2006) Belamide A: a new antimitotic tetrapeptide from a Panamanian marine cyanobacterium. Tetrahedron Lett 47:3387–3390
Sisay MT, Hautmann S, Mehner C, Konig GM, Bajorath J, Gutschow M (2009) Inhibition of human leukocyte elastase by brunsvicamides A–C: cyanobacterial cyclic peptides. Chem Med Chem 4:1425–1429
Smith CD, Zhang XQ, Moorbery SL, Patterson GML, Moore RE (1994) Cryptophycin—a new antimicrotubule agent active against drug-resistant cells. Cancer Res 54:3779–3784
Soni B, Trivedi U, Madamwar D (2008) A novel method of single step hydrophobic interaction chromatography for the purification of phycocyanin from Phormidium fragile and its characterization for antioxidant property. Bioresour Technol 99:188–194
Soria-Mercado IE, Pereira A, Cao Z, Murray TF, Gerwick WH (2009) Alotamide A, a novel neuropharmacological agent from the marine cyanobacterium Lyngbya bouillonii. Org Lett 11:4704–4707
Stevenson CS, Capper EA, Roshak AK, Marquez B, Grace K, Gerwick WH, Jacobs RS, Marshall LA (2002) Scytonemin—a marine natural product inhibitor of kinases key in hyper proliferative inflammatory diseases. Inflamm Res 51:112–114
Subhashini J, Mahipal SVK, Reddy MC, Mallikarjuna RM, Rachamallu A, Reddanna P (2004) Molecular mechanisms in C-Phycocyanin induced apoptosis in human chronic myeloid leukemia cell line -K 562. Biochem Pharmacol 68:453–462
Surakka A, Sihvonen LM, Lehtimaki JM, Wahlsten M, Vuorela P, Sivonen K (2005) Benthic cyanobacteria from Baltic Sea contain cytotoxic Anabaena, Nodularia and Nostoc strains and an apoptosis-inducing Phormidium strain. Environ Toxicol 20:285–292
Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219–234
Teruya T, Sasaki H, Kitamura K, Nakayama T, Suenaga K (2009) Biselyngbyaside, a macrolide glycoside from the marine cyanobacterium Lyngbya sp. Org Lett 11:2421–2424
Tan LT (2010) Filamentous tropical marine cyanobacteria: a rich source of natural products for anticancer drug discovery. J Appl Phycol 22:659–676
Thorburn A (2004) Death receptor-induced cell killing. Cell Signal 16:139–144
Trimurtulu G, Ohtani I, Patterson GM, Moore RE, Corbett TH, Valeriote FA, Demchik L (1994) Total structures of cryptophycins, potent antitumor depsipeptides from the blue-green alga Nostoc sp. strain GSV 224. J Am Chem Soc 116:4729–4737
Tripathi A, Puddick J, Prinsep MR, Rottmann M, Tan LT (2010) Lagunamides A and B: cytotoxic and antimalarial cyclodepsipeptides from the marine cyanobacterium Lyngbya majuscula. J Nat Prod 73:1810–1814
Tripathi A, Fang W, Leong DT, Tan LT (2012) Biochemical studies of the lagunamides, potent cytotoxic cyclic depsipeptides from the marine cyanobacterium Lyngbya majuscula. Mar Drugs 10:1126–1137
Trump BF, Berezesky IK (1995) Calcium-mediated cell injury and cell death. FASEB J 9:219–228
Uzair B, Tabassum S, Rasheed M, Rehman SF (2012) Exploring marine cyanobacteria for lead compounds of pharmaceutical importance. Sci World J 1–10.
Verdier-Pinard P, Lai JY, Yoo HD, Yu J, Marquez B, Nagle DG, Nambu M, White JD, Falck JR, Gerwick WH, Day BW, Hamel E (1998) Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells. Mol Pharmaco 53:62–76
Wang L, Pan B, Sheng J, Xu J, Hu Q (2007). Antioxidant activity of Spirulina platensis extracts by supercritical carbon dioxide extraction. Food Chem 105:36–41
Wang B, Huang PH, Chen CS, Forsyth CJ (2011) Total syntheses of the histone deacetylase inhibitors largazole and 2-epi-largazole: application of n-heterocyclic carbene mediated acylations in complex molecule synthesis. J Org Chem 76:1140–1150
Williams PG, Yoshida WY, Moore RE, Paul VJ (2002) Isolation and structure determination of obyanamide: a novel cytotoxic cyclic depsipeptide from the marine cyanobacterium Lyngbya confervoides. J Nat Prod 65:29–31
Williams PG, Yoshida WY, Moore RE, Paul VJ (2003a) Tasipeptins A and B: new cytotoxic depsipeptides from the marine cyanobacterium Symploca sp. J Nat Prod 66:620–624
Williams PG, Yoshida WY, Quon MK, Moore RE, Paul VJ (2003b) Ulongapeptin: a cytotoxic cyclic depsipeptide from a Palauan marine cyanobacterium Lyngbya sp. J Nat Prod 66:651–654
Williams PG, Yoshida WY, Moore RE, Paul VJ (2004) Micromide and guamamide: cytotoxic alkaloids from a species of the marine cyanobacterium Symploca. J Nat Prod 67:49–53
Wrasidlo W, Mielgo A, Torres VA, Barbero S, Stoletov K, Suyama TL, Klemke RL, Gerwick WH, Carson DA, Stupack DG (2008) The marine lipopeptide somocystinamide A triggers apoptosis via caspase 8. PNAS 105:2313–2318
Yokokawa F, Sameshima H, Shioiri T (2001) Total synthesis of lyngbyabellin a, a potent cytotoxic metabolite from the marine cyanobacterium Lyngbya majuscula. Tetrahedron Lett 42:4171–4174
Yonezawa T, Mase N, Sasaki H, Teruya T, Hasegawa S, Cha BY, Yagasaki K, Suenaga K, Nagai K, Woo JT (2012) Biselyngbyaside, isolated from marine cyanobacteria, inhibits osteoclastogenesis and induces apoptosis in mature osteoclasts. J Cell Biochem 113:440–448
Žegura B, Lah TT, Filipič M (2006) Alteration of intracellular GSH levels and its role in microcystin-LR-induced DNA damage in human hepatoma HepG2 cells. Mutat Res 611:25–33
Žegura B, Zajc I, Lah TT, Filipič M (2008) Patterns of microcystin-LR induced alteration of the expression of genes involved in response to DNA damage and apoptosis. Toxicon 51:615–623
Zhang JY (2002) Apoptosis-based anticancer drugs. Nat Rev Drug Discov 1:101–102
Zheng L, Lin X, Wu N, Liu M, Zheng Y, Sheng J, Xiaofeng JI, Sun M (2013) Targeting cellular apoptotic pathway with peptides from marine organisms. Biochim Biophys Acta 1836:42–48
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Mandal, S., Rath, J. (2015). Anticancer Drug Development from Cyanobacteria. In: Extremophilic Cyanobacteria For Novel Drug Development. SpringerBriefs in Pharmaceutical Science & Drug Development. Springer, Cham. https://doi.org/10.1007/978-3-319-12009-6_4
Download citation
DOI: https://doi.org/10.1007/978-3-319-12009-6_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-12008-9
Online ISBN: 978-3-319-12009-6
eBook Packages: MedicineMedicine (R0)